Ryvu Therapeutics presents new clinical and preclinical data for RVU120 program at 34th AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium
TitleFile
Current Report ESPI 24/2022
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPrivacy policy